The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Bile salts and cholestasis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
A G Protein-coupled Receptor Responsive to Bile Acids
Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209706200 · Cited by 1,628
Vitamin D Receptor As an Intestinal Bile Acid Sensor
Makishima, M., Lu, T. T., Xie, W., Whitfield, G. K., Domoto, H., Evans, R. M., Haussler, M. R., & Mangelsdorf, D. J. (2002) · Science · doi:10.1126/science.1070477 · Cited by 1,176
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R. T., Shelton, J. M., Richardson, J. A., Repa, J. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509592103 · Cited by 1,164 · cited 2×
“The exact mechanism of bile salt-mediated control of the intestinal flora remains to be further unraveled, but probably includes both direct effects on the growth of bacteria via accumulation of bile salts in the organisms [2,50], and indirect effects via bile salt-induced, FXR-mediated [51], antibacterial actions of…”
BackgroundParés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Paumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
Self-citationUrsodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727
Bile acids as regulatory molecules
Hylemon, P. B., Zhou, H., Pandak, W. M., Ren, S., Gil, G., & Dent, P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900007-jlr200 · Cited by 694 · cited 5×
“The ability of bile salts to activate the PI3K/AKT pathway that among others has an effect on the insertion of the glucose 4transporter (GLUT4) to the plasma membrane illustrates the effect of bile salt signaling on glucose metabolism [4,68–70].”
BackgroundInfluential
Research works printed but not linked: 167
- Hofmann, 2006, How bile acids confer gut mucosal protection against bacteria, Proc Natl Acad Sci USA, 103, 4333, 10.1073/pnas.0600780103 · DOI · Paper page
- Begley, 2005, The interaction between bacteria and bile, FEMS Microbiol Rev, 29, 625, 10.1016/j.femsre.2004.09.003 · DOI · Paper page
- Hofmann, 2008, Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics, Cell Mol Life Sci, 65, 2461, 10.1007/s00018-008-7568-6 · DOI · Paper page
- Zollner, 2009, Nuclear receptors as therapeutic targets in cholestatic liver diseases, Br J Pharmacol, 156, 7, 10.1111/j.1476-5381.2008.00030.x · DOI · Paper page
- Schmucker, 1990, Hepatic injury induced by bile salts: correlation between biochemical and morphological events, Hepatology, 12, 1216, 10.1002/hep.1840120523 · DOI · Paper page
- Hofmann, 1984, Physicochemical properties of bile acids and their relationship to biological properties: an overview of the problem, J Lipid Res, 25, 1477, 10.1016/S0022-2275(20)34421-7 · DOI · Paper page
- Griffiths, 2009, Bile acids: analysis in biological fluids and tissues, J Lipid Res, 10.1194/jlr.R001941 · DOI
- Hofmann, 2009, Bile salts of vertebrates: structural variation and possible evolutionary significance, J Lipid Res
- Monte, 2009, Bile acids: chemistry, physiology, and pathophysiology, World J Gastroenterol, 15, 804, 10.3748/wjg.15.804 · DOI · Paper page
- Perez, 2009, Bile-acid-induced cell injury and protection, World J Gastroenterol, 15, 1677, 10.3748/wjg.15.1677 · DOI · Paper page
- Roda, 1990, Physicochemical and biological properties of natural and synthetic C-22 and C-23 hydroxylated bile acids, J Lipid Res, 31, 289, 10.1016/S0022-2275(20)43214-6 · DOI
- Hofmann, 1992, Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions, J Lipid Res, 33, 617, 10.1016/S0022-2275(20)41426-9 · DOI · Paper page
- Hagey, 1993, Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores, J Lipid Res, 34, 1911, 10.1016/S0022-2275(20)35109-9 · DOI
- Sola, 2006, Plasma levels of ursodeoxycholic acid in black bears, Ursus americanus: seasonal changes, Comp Biochem Physiol C Toxicol Pharmacol, 143, 204, 10.1016/j.cbpc.2006.02.002 · DOI
- Poupon, 1993, Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy, Hepatology, 17, 599, 10.1002/hep.1840170412 · DOI
- Reddy, 1998, Faecal pH, bile acid and sterol concentrations in premenopausal Indian and white vegetarians compared with white omnivores, Br J Nutr, 79, 495, 10.1079/BJN19980087 · DOI
- van Faassen, 1993, Bile acids and pH values in total feces and in fecal water from habitually omnivorous and vegetarian subjects, Am J Clin Nutr, 58, 917, 10.1093/ajcn/58.6.917 · DOI
- Bisschop, 2004, Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans, Am J Clin Nutr, 79, 570, 10.1093/ajcn/79.4.570 · DOI
- Asakura, 2008, Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis?, J Gastroenterol Hepatol, 23, 1794, 10.1111/j.1440-1746.2008.05681.x · DOI
- Meier, 2002, Bile salt transporters, Annu Rev Physiol, 64, 635, 10.1146/annurev.physiol.64.082201.100300 · DOI · Paper page
- Strautnieks, 1998, A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis, Nat Genet, 20, 233, 10.1038/3034 · DOI · Paper page
- Duarte, 2009, Identification of metabolites in human hepatic bile using 800MHz 1H NMR spectroscopy, HPLC-NMR/MS and UPLC–MS. Mol Biosyst, 5, 180, 10.1039/B814426E · DOI
- Chari, 1996, Adenosine nucleotides in bile, Am J Physiol, 270, G246
- Chen, 2007, Two-dimensional electrophoresis for comparative proteomic analysis of human bile, Hepatobiliary Pancreat Dis Int, 6, 402
- Farina, 2009, Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer, J Proteome Res, 8, 159, 10.1021/pr8004925 · DOI
- Kristiansen, 2004, A proteomic analysis of human bile, Mol Cell Proteomics, 3, 715, 10.1074/mcp.M400015-MCP200 · DOI · Paper page
- Glickerman, 1997, The gallbladder also secretes, Dig Dis Sci, 42, 489, 10.1023/A:1018826521600 · doi:10.1023/a:1018826521600
- von Ritter, 1997, Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9, Anticancer Res, 17, 2931
- Hofmann, 2009, The enterohepatic circulation of bile acids in mammals: form and functions, Front Biosci, 14, 2584, 10.2741/3399 · DOI · Paper page
- Hruz, 2006, Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis, Gut, 55, 395, 10.1136/gut.2005.067389 · DOI
- Ballatori, 2008, Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver, Am J Physiol Gastrointest Liver Physiol, 295, G179, 10.1152/ajpgi.90319.2008 · DOI
- Ballatori, 2009, OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids, Front Biosci, 14, 2829, 10.2741/3416 · DOI
- Ma, 2009, Circadian dysregulation disrupts bile acid homeostasis, PLoS One, 4, e6843, 10.1371/journal.pone.0006843 · DOI
- Alpini, 2005, Secretin activation of the apical Na+-dependent bile acid transporter is associated with cholehepatic shunting in rats, Hepatology, 41, 1037, 10.1002/hep.20653 · DOI
- Xia, 2006, Bile acid interactions with cholangiocytes, World J Gastroenterol, 12, 3553, 10.3748/wjg.v12.i22.3553 · DOI · Paper page
- Fickert, 2006, 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice, Gastroenterology, 130, 465, 10.1053/j.gastro.2005.10.018 · DOI · Paper page
- Glaser, 2009, Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis, Hepatology, 49, 1795, 10.1002/hep.22969 · DOI
- Shindo, 1998, Omeprazole induces altered bile acid metabolism, Gut, 42, 266, 10.1136/gut.42.2.266 · DOI
- Beuers, 1991, Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man, J Hepatol, 13, 97, 10.1016/0168-8278(91)90870-H · DOI
- Toda, 2009, Ciprofloxacin suppresses Cyp3a in mouse liver by reducing lithocholic acid-producing intestinal flora, Drug Metab Pharmacokinet, 24, 201, 10.2133/dmpk.24.201 · DOI
- Lepercq, 2005, Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria, Br J Nutr, 93, 457, 10.1079/BJN20041386 · DOI
- Handschin, 2005, Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR, Arch Biochem Biophys, 433, 387, 10.1016/j.abb.2004.08.030 · DOI · Paper page
- Tietz, 2003, Agonist-induced coordinated trafficking of functionally related transport proteins for water and ions in cholangiocytes, J Biol Chem, 278, 20413, 10.1074/jbc.M302108200 · DOI
- Lam, 2009, Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP), Am J Physiol Gastrointest Liver Physiol, 297, G90, 10.1152/ajpgi.00094.2009 · DOI
- Gunnarsdottir, 2003, Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension, Am J Gastroenterol, 98, 1362, 10.1111/j.1572-0241.2003.07475.x · doi:10.1111/j.1572-0241.2003.07475.x · Paper page
- Slocum, 1992, Absence of intestinal bile promotes bacterial translocation, Am Surg, 58, 305
- D’Aldebert, 2009, Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium, Gastroenterology, 136, 1435, 10.1053/j.gastro.2008.12.040 · DOI · Paper page
- Stange, 2009, For bugs in bile: the times they are a-changin, Gastroenterology, 136, 1164, 10.1053/j.gastro.2009.02.020 · DOI
- Ding, 1993, The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats, Eur Surg Res, 25, 11, 10.1159/000129252 · DOI · Paper page
- Beuers, 1997, Effects of bile acids on hepatocellular signaling and secretion, Yale J Biol Med, 70, 341
- Anwer, 2004, Cellular regulation of hepatic bile acid transport in health and cholestasis, Hepatology, 39, 581, 10.1002/hep.20090 · DOI
- Zollner, 2006, Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations, Mol Pharm, 3, 231, 10.1021/mp060010s · DOI · Paper page
- Anwer, 1988, Hepatotoxic bile acids increase cytosolic Ca++ activity of isolated rat hepatocytes, Hepatology, 8, 887, 10.1002/hep.1840080430 · DOI
- Beuers, 1993, Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes, Gastroenterology, 104, 604, 10.1016/0016-5085(93)90433-D · DOI
- Beuers, 1996, Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes, Gastroenterology, 110, 1553, 10.1053/gast.1996.v110.pm8613063 · DOI
- Bouscarel, 1999, Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers, Gastroenterology, 117, 433, 10.1053/gast.1999.0029900433 · DOI
- Rao, 1997, Activation of protein kinase C alpha and delta by bile acids: correlation with bile acid structure and diacylglycerol formation, J Lipid Res, 38, 2446, 10.1016/S0022-2275(20)30029-8 · DOI
- Beuers, 1993, Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis, J Clin Invest, 92, 2984, 10.1172/JCI116921 · DOI · Paper page
- Misra, 1998, The role of phosphoinositide 3-kinase in taurocholate-induced trafficking of ATP-dependent canalicular transporters in rat liver, J Biol Chem, 273, 26638, 10.1074/jbc.273.41.26638 · DOI
- Misra, 1999, Phosphoinositide 3-kinase lipid products regulate ATP-dependent transport by sister of P-glycoprotein and multidrug resistance associated protein 2 in bile canalicular membrane vesicles, Proc Natl Acad Sci USA, 96, 5814, 10.1073/pnas.96.10.5814 · DOI
- Beuers, 2003, Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets, J Biol Chem, 278, 17810, 10.1074/jbc.M209898200 · DOI
- Haussinger, 2003, Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis, Gastroenterology, 124, 1476, 10.1016/S0016-5085(03)00274-9 · DOI
- Dent, 2005, Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes, Hepatology, 42, 1291, 10.1002/hep.20942 · DOI
- Nguyen, 2008, Bile acids and signal transduction: role in glucose homeostasis, Cell Signal, 20, 2180, 10.1016/j.cellsig.2008.06.014 · DOI · Paper page
- Lefebvre, 2009, Role of bile acids and bile acid receptors in metabolic regulation, Physiol Rev, 89, 147, 10.1152/physrev.00010.2008 · DOI · Paper page
- Zhang, 2006, Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice, Proc Natl Acad Sci USA, 103, 1006, 10.1073/pnas.0506982103 · DOI · Paper page
- Houten, 2006, Endocrine functions of bile acids, EMBO J, 25, 1419, 10.1038/sj.emboj.7601049 · DOI · Paper page
- Keitel, 2008, Endocrine and paracrine role of bile acids, World J Gastroenterol, 14, 5620, 10.3748/wjg.14.5620 · DOI
- Ikemoto, 1997, Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease, Am J Physiol, 273, E37
- Ishizawa, 2008, Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia, J Lipid Res, 49, 763, 10.1194/jlr.M700293-JLR200 · DOI
- Yamazaki, 2001, Bile acids induce eosinophil degranulation by two different mechanisms, Hepatology, 33, 582, 10.1053/jhep.2001.22168 · doi:10.1053/jhep.2001.22168
- Bergamini, 1997, Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells, Hepatology, 25, 927, 10.1002/hep.510250423 · DOI
- Oumi, 2000, A scanning electron microscope study on the effects of different bile salts on the epithelial lining of jejunal mucosa, Med Electron Microsc, 33, 11, 10.1007/s007950000002 · DOI
- Benedetti, 1997, Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver, Hepatology, 26, 9, 10.1002/hep.510260102 · DOI
- Hofmann, 1999, The continuing importance of bile acids in liver and intestinal disease, Arch Intern Med, 159, 2647, 10.1001/archinte.159.22.2647 · DOI · Paper page
- Palmeira, 2004, Mitochondrially-mediated toxicity of bile acids, Toxicology, 203, 1, 10.1016/j.tox.2004.06.001 · DOI · Paper page
- Sokol, 1998, Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat, Gastroenterology, 114, 164, 10.1016/S0016-5085(98)70644-4 · DOI · Paper page
- Schubert, 1988, Structural changes in vesicle membranes and mixed micelles of various lipid compositions after binding of different bile salts, Biochemistry, 27, 8787, 10.1021/bi00424a015 · DOI
- Lemasters, 1998, The mitochondrial permeability transition: from biochemical curiosity to pathophysiological mechanism, Gastroenterology, 115, 783, 10.1016/S0016-5085(98)70160-X · DOI
- Lemasters, 1998, The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy, Biochim Biophys Acta, 1366, 177, 10.1016/S0005-2728(98)00112-1 · DOI · Paper page
- Lemasters, 2009, Mitochondrial calcium and the permeability transition in cell death, Biochim Biophys Acta, 1787, 1395, 10.1016/j.bbabio.2009.06.009 · DOI · Paper page
- Sokol, 2005, Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids, J Pediatr Gastroenterol Nutr, 41, 235, 10.1097/01.MPG.0000170600.80640.88 · DOI
- Rolo, 2003, Mitochondrially mediated synergistic cell killing by bile acids, Biochim Biophys Acta, 1637, 127, 10.1016/S0925-4439(02)00224-7 · DOI
- Sokol, 1995, Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids, Gastroenterology, 109, 1249, 10.1016/0016-5085(95)90585-5 · DOI · Paper page
- Gumpricht, 2008, Resistance of young rat hepatic mitochondria to bile acid-induced permeability transition: potential role of alpha-tocopherol, Pediatr Res, 64, 498, 10.1203/PDR.0b013e3181841ee1 · DOI
- Yerushalmi, 2001, Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition, Hepatology, 33, 616, 10.1053/jhep.2001.22702 · DOI · Paper page
- Prince, 2003, Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial, Aliment Pharmacol Ther, 17, 137, 10.1046/j.1365-2036.2003.01398.x · DOI
- Reinehr, 2003, Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation, Gastroenterology, 125, 839, 10.1016/S0016-5085(03)01055-2 · DOI
- Reinehr, 2005, Bile salt-induced apoptosis involves NADPH oxidase isoform activation, Gastroenterology, 129, 2009, 10.1053/j.gastro.2005.09.023 · DOI
- Rust, 2009, Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent, J Biol Chem, 284, 2908, 10.1074/jbc.M804585200 · DOI
- Kim, 2008, Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities, Nat Rev Drug Discov, 7, 1013, 10.1038/nrd2755 · DOI · Paper page
- Kaplowitz, 2007, Endoplasmic reticulum stress and liver injury, Semin Liver Dis, 27, 367, 10.1055/s-2007-991513 · DOI
- Iizaka, 2007, Interaction between caspase-8 activation and endoplasmic reticulum stress in glycochenodeoxycholic acid-induced apoptotic HepG2 cells, Toxicology, 241, 146, 10.1016/j.tox.2007.08.095 · DOI
- Hitomi, 2004, Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death, J Cell Biol, 165, 347, 10.1083/jcb.200310015 · DOI · Paper page
- Bochkis, 2008, Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress, Nat Med, 14, 828, 10.1038/nm.1853 · DOI · Paper page
- Kitani, 1985, Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat, Am J Physiol, 248, G407
- Wimmer, 2008, Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver, Gut, 57, 1448, 10.1136/gut.2007.140871 · DOI
- Marzioni, 2006, Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts, Am J Pathol, 168, 398, 10.2353/ajpath.2006.050126 · DOI
- Lazaridis, 2001, Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’, J Hepatol, 35, 134, 10.1016/S0168-8278(01)00092-7 · DOI · Paper page
- Beuers, 1998, Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications, Hepatology, 28, 1449, 10.1002/hep.510280601 · DOI · Paper page
- Dombrowski, 2006, Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver, Lab Invest, 86, 166, 10.1038/labinvest.3700371 · DOI
- Beuers, 2001, Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver, Hepatology, 33, 1206, 10.1053/jhep.2001.24034 · DOI · Paper page
- Fiorotto, 2007, Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion, Gastroenterology, 133, 1603, 10.1053/j.gastro.2007.08.071 · DOI
- Minagawa, 2007, Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile, Gastroenterology, 133, 1592, 10.1053/j.gastro.2007.08.020 · DOI
- Nathanson, 2001, Stimulation of ATP secretion in the liver by therapeutic bile acids, Biochem J, 358, 1, 10.1042/0264-6021:3580001 · DOI
- Rodrigues, 1998, A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation, J Clin Invest, 101, 2790, 10.1172/JCI1325 · DOI · Paper page
- Serviddio, 2004, Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress, Hepatology, 39, 711, 10.1002/hep.20101 · DOI
- Rodrigues, 2001, The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent, Expert Opin Investig Drugs, 10, 1243, 10.1517/13543784.10.7.1243 · DOI
- Mitsuyoshi, 1999, Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants, Biochem Biophys Res Commun, 263, 537, 10.1006/bbrc.1999.1403 · DOI · Paper page
- Heathcote, 1994, The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis, Hepatology, 19, 1149, 10.1002/hep.1840190512 · DOI · Paper page
- Lindor, 1994, Ursodeoxycholic acid in the treatment of primary biliary cirrhosis, Gastroenterology, 106, 1284, 10.1016/0016-5085(94)90021-3 · DOI · Paper page
- Combes, 1995, A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis, Hepatology, 22, 759
- Pares, 2000, Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver, J Hepatol, 32, 561, 10.1016/S0168-8278(00)80216-0 · DOI · Paper page
- Shi, 2006, Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials, Am J Gastroenterol, 101, 1529, 10.1111/j.1572-0241.2006.00634.x · DOI
- Lindor, 2000, Ursodeoxycholic acid for primary biliary cirrhosis, Lancet, 355, 657, 10.1016/S0140-6736(05)72401-6 · DOI
- Corpechot, 2005, The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis, Gastroenterology, 128, 297, 10.1053/j.gastro.2004.11.009 · DOI · Paper page
- Kuiper, 2009, Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid, Gastroenterology, 136, 1281, 10.1053/j.gastro.2009.01.003 · DOI · Paper page
- O’Brien, 1991, Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study, Hepatology, 14, 838, 10.1002/hep.1840140516 · DOI · Paper page
- Beuers, 1992, Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial, Hepatology, 16, 707, 10.1002/hep.1840160315 · DOI · Paper page
- Stiehl, 1994, Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis, Scand J Gastroenterol Suppl, 204, 59, 10.3109/00365529409103626 · DOI
- Rost, 2004, Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis, Hepatology, 40, 693, 10.1002/hep.20370 · DOI
- Mitchell, 2001, A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis, Gastroenterology, 121, 900, 10.1053/gast.2001.27965 · DOI · Paper page
- Harnois, 2001, High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis, Am J Gastroenterol, 96, 1558, 10.1111/j.1572-0241.2001.03777.x · DOI · Paper page
- Lindor, 2009, High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis, Hepatology, 50, 808, 10.1002/hep.23082 · DOI · Paper page
- Lindor, 2008, Randomized, double-blind controlled trial of high-dose ursodeoxycholic acid for primary sclerosing cholangitis, Hepatology, 48, 378A
- Bergquist, 2002, Hepatic and extrahepatic malignancies in primary sclerosing cholangitis, J Hepatol, 36, 321, 10.1016/S0168-8278(01)00288-4 · DOI · Paper page
- Tung, 2001, Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis, Ann Intern Med, 134, 89, 10.7326/0003-4819-134-2-200101160-00008 · DOI · Paper page
- Wolf, 2005, The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis, Aliment Pharmacol Ther, 22, 783, 10.1111/j.1365-2036.2005.02650.x · DOI
- Pardi, 2003, Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis, Gastroenterology, 124, 889, 10.1053/gast.2003.50156 · DOI · Paper page
- Rudolph, 2007, The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid, Eur J Gastroenterol Hepatol, 19, 487, 10.1097/MEG.0b013e3281108068 · DOI
- Lazaridis, 2006, Primary sclerosing cholangitis and cholangiocarcinoma, Semin Liver Dis, 26, 42, 10.1055/s-2006-933562 · DOI
- Brandsaeter, 2004, Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy, J Hepatol, 40, 815, 10.1016/j.jhep.2004.01.002 · DOI · Paper page
- Palma, 1997, Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo, J Hepatol, 27, 1022, 10.1016/S0168-8278(97)80146-8 · DOI · Paper page
- Williamson, 2004, Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group, BJOG, 111, 676, 10.1111/j.1471-0528.2004.00167.x · DOI
- Roncaglia, 2004, A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis, BJOG, 111, 17, 10.1046/j.1471-0528.2003.00029.x · DOI
- Glantz, 2005, Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid, Hepatology, 42, 1399, 10.1002/hep.20952 · DOI · Paper page
- Kondrackiene, 2005, Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy, Gastroenterology, 129, 894, 10.1053/j.gastro.2005.06.019 · DOI · Paper page
- Binder, 2006, Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy, J Perinat Med, 34, 383, 10.1515/JPM.2006.077 · DOI
- Glantz, 2008, Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine, Hepatology, 47, 544, 10.1002/hep.21987 · DOI
- Colombo, 1996, Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis, Hepatology, 23, 1484, 10.1002/hep.510230627 · DOI · Paper page
- van de Meeberg, 1997, Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up, Scand J Gastroenterol, 32, 369, 10.3109/00365529709007686 · DOI
- Lindblad, 1998, A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease, Hepatology, 27, 166, 10.1002/hep.510270126 · DOI · Paper page
- Davit-Spraul, 2009, Progressive familial intrahepatic cholestasis, Orphanet J Rare Dis, 4, 1, 10.1186/1750-1172-4-1 · DOI · Paper page
- Jacquemin, 2001, The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood, Gastroenterology, 120, 1448, 10.1053/gast.2001.23984 · DOI · Paper page
- Nathwani, 2006, Drug hepatotoxicity, Clin Liver Dis, 10, 207, 10.1016/j.cld.2006.05.009 · DOI
- Essell, 1998, Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 128, 975, 10.7326/0003-4819-128-12_Part_1-199806150-00002 · DOI · Paper page
- Ohashi, 2000, The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation, Am J Hematol, 64, 32, 10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N · doi:10.1002/(sici)1096-8652(200005)64:1<32::aid-ajh6>3.0.co;2-n
- Ruutu, 2002, Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation, Blood, 100, 1977, 10.1182/blood-2001-12-0159 · DOI · Paper page
- Tay, 2007, Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 13, 206, 10.1016/j.bbmt.2006.09.012 · DOI
- DeLeve, 2009, Vascular disorders of the liver, Hepatology, 49, 1729, 10.1002/hep.22772 · DOI · Paper page
- 2009, European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B, J Hepatol, 50, 227, 10.1016/j.jhep.2008.10.001 · DOI · Paper page
- Ghany, 2009, Diagnosis, management, and treatment of hepatitis C: an update, Hepatology, 49, 1335, 10.1002/hep.22759 · DOI · Paper page
- Pelletier, 2003, A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice, Hepatology, 37, 887, 10.1053/jhep.2003.50118 · DOI
- Mancinelli, 2009, Taurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression, Exp Biol Med (Maywood), 234, 462, 10.3181/0808-RM-255 · DOI
- Ueno, 2007, Taurocholic acid feeding prevents tumor necrosis factor-alpha-induced damage of cholangiocytes by a PI3K-mediated pathway, Exp Biol Med (Maywood), 232, 942
- Marzioni, 2007, Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver, Liver Int, 27, 558, 10.1111/j.1478-3231.2007.01443.x · DOI
- Sundaram, 2008, Mechanisms of disease: inborn errors of bile acid synthesis, Nat Clin Pract Gastroenterol Hepatol, 5, 456, 10.1038/ncpgasthep1179 · DOI · Paper page
- Oude Elferink, 2006, Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases, Gastroenterology, 130, 908, 10.1053/j.gastro.2005.08.052 · DOI · Paper page
- Heubi, 2007, Inborn errors of bile acid metabolism, Semin Liver Dis, 27, 282, 10.1055/s-2007-985073 · DOI
- Gonzales, 2009, Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy, Gastroenterology, 137, 10.1053/j.gastro.2009.07.043 · DOI
- Halilbasic, 2009, Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice, Hepatology, 49, 1972, 10.1002/hep.22891 · DOI
- Hofmann, 2005, Novel biotransformation and physiological properties of norursodeoxycholic acid in humans, Hepatology, 42, 1391, 10.1002/hep.20943 · DOI
- Hofmann, 2009, Bile acids: trying to understand their chemistry and biology with the hope of helping patients, Hepatology, 49, 1403, 10.1002/hep.22789 · DOI · Paper page
- Yoon, 1986, Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents, Gastroenterology, 90, 837, 10.1016/0016-5085(86)90859-0 · DOI · Paper page
- Cipriani, 2009, FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats, J Lipid Res
- Fiorucci, 2005, Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis, J Pharmacol Exp Ther, 313, 604, 10.1124/jpet.104.079665 · DOI · Paper page
- Wang, 2009, Farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria, Am J Physiol Renal Physiol, 10.1152/ajprenal.00404.2009 · DOI · Paper page
Cited by
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationModulation of the fecal bile acid profile by gut microbiota in cirrhosis
Kakiyama, G., Pandak, W. M., Gillevet, P. M., Hylemon, P. B., Heuman, D. M., Daita, K., Takei, H., Muto, A., Nittono, H., Ridlon, J. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.01.003 · Cited by 781
Lai, J. C., Tandon, P., Bernal, W., Tapper, E. B., Ekong, U., Dasarathy, S., & Carey, E. J. (2021) · Hepatology · doi:10.1002/hep.32049 · Cited by 742
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
Apoptosis and Necrosis in the Liver
Guicciardi, M. E., Malhi, H., Mott, J. L., & Gores, G. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120020 · Cited by 353
Metadata
- Authors
- Maillette de Buy Wenniger, L., & Beuers, U.
- Venue
- Digestive and Liver Disease
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 42
- Issue
- 6
- Pages
- 409-418
- ISSN
- 1590-8658 (ISSN-L)
- OpenAlex
- W2133074258
- Cited by
- 162
- References
- 23
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bile salts and cholestasis. https://app.cochat.ai/papers/10.1016/j.dld.2010.03.015
- The paper
- Maillette de Buy Wenniger, L., & Beuers, U. (2010). Bile salts and cholestasis. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2010.03.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.